The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Fibroblast Growth Factor Signaling in Metabolic Regulation
|
|---|---|
| Published in |
Frontiers in endocrinology, January 2016
|
| DOI | 10.3389/fendo.2015.00193 |
| Pubmed ID | |
| Authors |
Vera J. M. Nies, Gencer Sancar, Weilin Liu, Tim van Zutphen, Dicky Struik, Ruth T. Yu, Annette R. Atkins, Ronald M. Evans, Johan W. Jonker, Michael Robert Downes |
| Abstract |
The prevalence of obesity is a growing health problem. Obesity is strongly associated with several comorbidities, such as non-alcoholic fatty liver disease, certain cancers, insulin resistance, and type 2 diabetes, which all reduce life expectancy and life quality. Several drugs have been put forward in order to treat these diseases, but many of them have detrimental side effects. The unexpected role of the family of fibroblast growth factors in the regulation of energy metabolism provides new approaches to the treatment of metabolic diseases and offers a valuable tool to gain more insight into metabolic regulation. The known beneficial effects of FGF19 and FGF21 on metabolism, together with recently discovered similar effects of FGF1 suggest that FGFs and their derivatives carry great potential as novel therapeutics to treat metabolic conditions. To facilitate the development of new therapies with improved targeting and minimal side effects, a better understanding of the molecular mechanism of action of FGFs is needed. In this review, we will discuss what is currently known about the physiological roles of FGF signaling in tissues important for metabolic homeostasis. In addition, we will discuss current concepts regarding their pharmacological properties and effector tissues in the context of metabolic disease. Also, the recent progress in the development of FGF variants will be reviewed. Our goal is to provide a comprehensive overview of the current concepts and consensuses regarding FGF signaling in metabolic health and disease and to provide starting points for the development of FGF-based therapies against metabolic conditions. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 217 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 2 | <1% |
| Japan | 1 | <1% |
| France | 1 | <1% |
| Unknown | 213 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 43 | 20% |
| Student > Master | 37 | 17% |
| Researcher | 31 | 14% |
| Student > Bachelor | 23 | 11% |
| Student > Postgraduate | 10 | 5% |
| Other | 31 | 14% |
| Unknown | 42 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 60 | 28% |
| Agricultural and Biological Sciences | 36 | 17% |
| Medicine and Dentistry | 35 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
| Sports and Recreations | 5 | 2% |
| Other | 20 | 9% |
| Unknown | 51 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2022.
All research outputs
#2,276,811
of 26,106,397 outputs
Outputs from Frontiers in endocrinology
#636
of 13,353 outputs
Outputs of similar age
#37,662
of 406,113 outputs
Outputs of similar age from Frontiers in endocrinology
#4
of 30 outputs
Altmetric has tracked 26,106,397 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,353 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,113 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.